VIENNA, Austria and KING OF PRUSSIA, Pa., Nov. 16, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) – Nabriva Therapeutics AG, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today reported its financial results for the three and nine months ended September 30, 2016.
“In the third quarter, we diligently advanced our clinical development program with lefamulin for the treatment of Community Acquired Bacterial Pneumonia (CABP),” said Dr. Colin Broom, Chief Executive Officer of Nabriva. “Based on our current enrollment estimates, we remain on schedule to reach our goal of 60% enrollment for our first global registrational trial, Lefamulin Evaluation Against Pneumonia (LEAP) 1, later this year. Additionally, based on our estimates regarding patient enrollment in our two ongoing Phase 3 clinical trials for the treatment of CABP, we continue to believe our current cash resources will be sufficient to fund our operations through the receipt of top-line clinical data from both of these Phase 3 CABP trials, which is anticipated in the second half of next year.”
